Clinical trial
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed…
NCT00283803 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00283803 |
|---|---|
| Title | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer |
| Official title | Evaluation of the Effect of Exisulind on the Duration of the "Off-Treatment" Interval on Patients With Biochemical Relapse of Prostate Cancer Who Are Treated With Intermittent Androgen Suppression (ADT) |
| Lead sponsor | University of Washington, Other |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen |
| Enrollment | 32 |
| Start date | Mar 12, 2002 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jan 30, 2006 |
| Last update posted | Aug 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: